Methyl (Z)-3-amino-4,4-dimethoxy-2-butenoate | 116274-13-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Methyl (Z)-3-amino-4,4-dimethoxy-2-butenoate
• 英文别名: methyl 4,4-dimethoxy-3-aminocrotonate；Methyl 3-amino-4,4-dimethoxycrotonate；methyl (Z)-3-amino-4,4-dimethoxybut-2-enoate
• CAS: 116274-13-6
• 化学式: C₇H₁₃NO₄
• 分子量: 175.185
• InChiKey: RGAHQPXNVPJMRO-PLNGDYQASA-N

物化性质

• 沸点：
  268.3±40.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(1-(2-Nitrobenzylidene)-acetonyl)-2-oxo-1,3,2-dioxaphosphorinane 、 Methyl (Z)-3-amino-4,4-dimethoxy-2-butenoate 以35%的产率得到
  参考文献：
  名称：

  MORITA, IWAO;HARUTA, YUKO;TOMITA, TOSHIO;TSUDA, MASAMI;KANDORI, KAZUHISA;+, CHEM. AND PHARM. BULL., 35,(1987) N 12, 4819-4828

  摘要：

  DOI：
• 作为产物：
  描述：

  Methyl (E)-3-bromo-4,4-dimethoxy-2-butenoate 在 ammonium hydroxide 作用下， 以 四氯化碳 为溶剂， 反应 26.0h， 生成 Methyl (Z)-3-amino-4,4-dimethoxy-2-butenoate
  参考文献：
  名称：

  Ancos, Begona de; Maestro, M. Carmen; Martin, M. Rosario, Synthesis, 1988, # 2, p. 136 - 138

  摘要：

  DOI：

文献信息

• 2-Substituted or unsubstituted aminocarbonyloxyalkyl-1,4-dihydropyridines
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US04404378A1

  公开（公告）日：1983-09-13

  Novel compounds having vasodilation and hypotensive effects are represented by the formula ##STR1## where R.sup.1 is halogen, nitro, cyano or lower alkoxy; each of R.sup.2 and R.sup.3 is lower alkyl, lower haloalkyl, lower alkoxyalkyl, aralkyloxyalkyl, aryloxyalkyl, lower alkenoxyalkyl, N,N-di-lower alkylaminoalkyl, N-lower alkyl-N-aralkylaminoalkyl, piperidylalkyl, 4-lower alkyl piperazinylalkyl, norpholinoalkyl or 1-pyrrolidinylalkyl; R.sup.4 is lower alkyl; A is lower alkylene; and R.sup.5 is hydrogen, lower alkyl, cycloalkyl of 3 to 7 carbon atoms, or aryl unsubstituted or substituted by one or two substituents selected from halogen, nitro, lower alkyl, lower alkoxy, di-lower alkylamino and cyano. Also disclosed are processes for their preparation.

  具有扩血管和降压作用的新化合物由以下式表示##STR1##其中R.sup.1为卤素、硝基、氰基或较低的烷氧基；R.sup.2和R.sup.3中的每一个为较低的烷基、较低的卤代烷基、较低的烷氧基烷基、芳基氧基烷基、芳基氧基烷基、较低的烯氧基烷基、N,N-二较低烷基氨基烷基、N-较低烷基-N-芳基氨基烷基、哌啶基烷基、4-较低烷基哌嗪基烷基、吗啉基烷基或1-吡咯啉基烷基；R.sup.4为较低的烷基；A为较低的烷基；R.sup.5为氢、较低的烷基、3至7个碳原子的环烷基，或者未取代或取代一个或两个卤素、硝基、较低烷基、较低烷氧基、二较低烷基氨基和氰基中的一种或两种取代基的芳基。还公开了它们的制备方法。
• Pyridazinone compound and pharmaceutical use thereof
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US20040067955A1

  公开（公告）日：2004-04-08

  A pyridazinone or pyridone compound of the following formula (I). 1 wherein X is 2 Y is N or CH or a salt thereof. The pyridazinone or pyridone compound (I) and a salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like.

  以下是化学式（I）的吡啶并嗪酮或吡啶酮化合物： 其中，X为2，Y为N或CH，或其盐。 本发明的吡啶并嗪酮或吡啶酮化合物（I）及其盐是腺苷拮抗剂，可用于预防和/或治疗抑郁症、痴呆症（例如阿尔茨海默病、脑血管性痴呆、帕金森病相关的痴呆等）、帕金森病、焦虑症、疼痛、脑血管疾病（例如中风等）、心力衰竭等。
• [EN] PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CaV1.2 ACTIVATORS<br/>[FR] COMPOSÉS DE PYRIDINE-3-CARBOXYLATE UTILISÉS EN TANT QU'ACTIVATEURS DE CAV1.2
  申请人：NOVARTIS AG

  公开号：WO2023111799A1

  公开（公告）日：2023-06-22

  The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

  本公开提供了一种根据式（I）的化合物或其药学上可接受的盐作为Cav1.2激活剂，用于治疗精神分裂症、双相情感障碍、重度抑郁障碍、药物使用障碍、多动症、菲兰-麦克德米综合征、自闭症谱系障碍、多发性硬化症、额颞叶痴呆症、阿尔茨海默病、Brugada综合征、短QT综合征或早期再极化综合征。
• 2,6-Disubstituted-1,4-dihydropyridine derivative, process for the preparation of the same and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0127150A2

  公开（公告）日：1984-12-05

  A compound of the formula: in which R' is aryl which may have one or more suitable substituent(s) or a heterocyclic group, R' is an esterfied carboxy group, R3 is lower alkyl, acyl, protected acyl or cyano, R4 is lower alkyl and A is lower alkylene, and pharmaceutically acceptable salt thereof, processes for its preparation and pharmaceutical compositions, containing them in association with pharmaceutical carrier or diluent. The invention also relates to intermediates for preparing the above compounds.

  以下式子的化合物 其中 R' 为芳基，可带有一个或多个合适的取代基，或杂环基、 R' 是酯化羧基、 R3 是低级烷基、酰基、受保护酰基或氰基、 R4 是低级烷基 A 是低级亚烷基、 及其药学上可接受的盐、制备方法和药物组合物，其中含有与药物载体或稀释剂结合的这些物质。本发明还涉及制备上述化合物的中间体。
• Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them
  申请人：FISONS plc

  公开号：EP0174131A2

  公开（公告）日：1986-03-12

  There are described compounds of formula 1, in which R,, R2, R3, Rs and R6 are as defined in the specification and R4 is a phenyl group carrying 3 or 4 substituents or is an unsaturated 5 membered heterocyclic group containing a single hetero-atom selected from oxygen, sulphur or nitrogen, R4 being substituted by CF3, XR22, nitro, halogen, CN, alkyl C1 to 6, formyl dioxalanyl, -N(R23)COR24 -CONR25R26, or amino which is optionally substituted by phenylsulphonyl or by trifluoroacetyl, and R4 carries a substituent on the atom adjacent to the atom through which R4 is connected to the remainder of the molecule, R22 is phenyl or alkyl C1 to 6 optionally substituted by halogen, X is 0 or S(O)n, n is 0, 1 or 2, and R23, R24, R25 and R26, which may be the same or different, are each hydrogen or alkyl C1 to 6. There are also described methods for making the compounds, and their formulation and use as pharmaceuticals, eg for the treatment of cardiovascular conditions. There are further described compounds R4CHO which are useful in making compounds of formula I.

  所述化合物为式 1、 其中 R,、R2、R3、Rs 和 R6 如说明书中所定义，R4 是带有 3 或 4 个取代基的苯基，或者是含有一个选自氧、硫或氮的杂原子的不饱和 5 位杂环基团，R4 被 CF3、XR22、R4被 CF3、XR22、硝基、卤素、CN、C1-6 烷基、二噁烷甲酰基、-N(R23)COR24-CONR25R26 或任选被苯磺酰基或三氟乙酰基取代的氨基取代，且 R4 在与 R4 通过其与分子其余部分相连的原子相邻的原子上带有一个取代基、 R22 是苯基或任选被卤素取代的 C1 至 6 烷基、 X 是 0 或 S(O)n、 n 是 0、1 或 2，以及 R23、R24、R25 和 R26（可以相同或不同）各自为氢或 C1-6 烷基。 还描述了制造这些化合物的方法，以及它们作为药物的配制和使用，例如用于治疗心血管疾病。 此外，还描述了可用于制造式 I 化合物的 R4CHO 化合物。